Chicago, IL—Treatment with the immune checkpoint inhibitor pembroliz­umab (Keytruda) dramatically improved 5-year survival for patients with advanced non–small-cell lung cancer (NSCLC) compared with expected survival in the preimmunotherapy era, according to the 5-year follow-up data from the phase 1b KEYNOTE-001 clinical trial. The study was presented at ASCO 2019 and was published simultaneously in the Journal of Clinical Oncology.

Virtually all patients that succumb to prostate cancer die of metastatic castration-resistant disease (CRPC). Docetaxel, the standard of care for these patients, provides a modest prolongation of survival, but there is an urgent need for novel treatment strategies.

Chicago, IL—BLU-667, a novel inhibitor of RET, elicited responses in more than 50% of patients with RET fusion–positive advanced non–small-cell lung cancer (NSCLC), according to data from an ongoing phase 1 clinical trial presented at ASCO 2019.